Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01557881 | Positron Emission Tomography/Magnetic Resonance Imaging in Patients | N/A | terminated | Mar 20, 2012 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT01970527 | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating… | Phase 2 | terminated | Oct 28, 2013 | University of Washington | Change in standard of care | Other (stated, no rule matched) |
| NCT04125719 | PVSRIPO in Combination With Nivolumab in Melanoma(PPD1) | Phase 1 | withdrawn | Oct 14, 2019 | Darell Bigner | resubmission planned | Other (stated, no rule matched) |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT03022565 | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma | Early Phase 1 | withdrawn | Jan 16, 2017 | University of Miami | Investigator Decision | Investigator |
| NCT02828345 | Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma | — | withdrawn | Jul 11, 2016 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT04007588 | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or… | Phase 2 | withdrawn | Jul 5, 2019 | Dana-Farber Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT02587650 | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS… | Phase 2 | terminated | Oct 27, 2015 | University of California, San Francisco | Funding | Funding |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to… | Phase 1 | terminated | Dec 18, 2013 | Eli Lilly and Company | This trial was terminated early based on the lack of sufficient clinical efficacy observed. | Efficacy / futility |
| NCT01437605 | Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or… | Phase 2 | terminated | Sep 21, 2011 | H. Lee Moffitt Cancer Center and Research Institute | Treatment Ineffective | Other (stated, no rule matched) |
| NCT03321903 | EPR Tumor Oximetry With CE India Ink | — | terminated | Oct 26, 2017 | Philip Schaner | The research team is exploring device optimization | Other (stated, no rule matched) |
| NCT01336985 | Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads | Phase 1 | terminated | Apr 18, 2011 | National Institutes of Health Clinical Center (CC) | not stated | Not stated |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients… | Phase 2 | terminated | Oct 4, 2017 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT01218867 | CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | Phase 1 / Phase 2 | terminated | Oct 11, 2010 | National Cancer Institute (NCI) | No objective responses were observed. | Other (stated, no rule matched) |
| NCT01369875 | Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | Phase 2 | terminated | Jun 9, 2011 | National Cancer Institute (NCI) | Premature closure. Protocol did not meet its primary objective. | Other (stated, no rule matched) |
| NCT02190838 | Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone… | Phase 2 | terminated | Jul 15, 2014 | N.N. Petrov National Medical Research Center of Oncology | Preliminary terminated due to inefficacy | Other (stated, no rule matched) |
| NCT01585415 | Vemurafenib and White Blood Cell Therapy for Advanced Melanoma | Phase 1 | terminated | Apr 25, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | Phase 2 | terminated | May 2, 2008 | National Cancer Institute (NCI) | A more highly selected protocol with ESO TCR opened for pts with melanoma | Other (stated, no rule matched) |
| NCT01264081 | Lapatinib in Stage IV Melanoma With ERBB4 Mutations | Phase 2 | terminated | Dec 21, 2010 | National Cancer Institute (NCI) | Protocol would not be able to reach stated accrual. | Enrollment / accrual |
| NCT02744209 | Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients | — | terminated | Apr 20, 2016 | Mayo Clinic | Low accrual | Enrollment / accrual |
| NCT03982134 | PDR001 + Panobinostat for Melanoma and NSCLC | Phase 1 | withdrawn | Jun 11, 2019 | Muhammad Furqan | Sponsor decision to withdraw | Sponsor / business decision |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With… | Phase 1 | terminated | Mar 17, 2016 | Novartis Pharmaceuticals | considering the limited clinical activity observed with LTT462, the decision was made to not open… | Other (stated, no rule matched) |
| NCT02359851 | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | Phase 2 | terminated | Feb 10, 2015 | Vanderbilt-Ingram Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02302339 | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in… | Phase 2 | terminated | Nov 27, 2014 | Celldex Therapeutics | Development of glembatumumab vedotin was discontinued | Other (stated, no rule matched) |
| NCT01471054 | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque… | Phase 2 | terminated | Nov 11, 2011 | Arman Mashayekhi | Could not enroll enough patients. | Enrollment / accrual |
| NCT00729807 | 0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma | Phase 2 | terminated | Aug 8, 2008 | University of Maryland, Baltimore | Study was closed at the suggestion of DSMB prior to obtaining target enrollment | Enrollment / accrual |
| NCT00346372 | Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus,… | — | terminated | Jun 29, 2006 | Jonsson Comprehensive Cancer Center | low accrual | Enrollment / accrual |
| NCT00571116 | Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One… | Phase 1 | terminated | Dec 11, 2007 | University of California, Irvine | Halted because of slow accrual and lack of study funding | Enrollment / accrual |
| NCT03391050 | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600… | Phase 1 / Phase 2 | terminated | Jan 5, 2018 | Aprea Therapeutics | Target patient population - difficult to find patientes | Other (stated, no rule matched) |
| NCT03552549 | SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500,… | Phase 2 / Phase 3 | terminated | Jun 12, 2018 | Merck Sharp & Dohme LLC | This study was closed to enrollment prematurely due to sub-optimal accrual. | Enrollment / accrual |
| NCT02891616 | 18F-FLT PET Imaging in Patients With Advanced Melanoma | Phase 1 | terminated | Sep 7, 2016 | Washington University School of Medicine | Low accrual rate | Enrollment / accrual |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | Phase 1 / Phase 2 | withdrawn | Apr 13, 2017 | William Grosh, MD | funding was withdrawn | Funding |
| NCT02005614 | A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI… | N/A | terminated | Dec 9, 2013 | Yale University | Unable to recruit patients. | Enrollment / accrual |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who… | Phase 1 / Phase 2 | terminated | Jun 3, 2014 | National Cancer Institute (NCI) | Slow, insufficient accrual. | Enrollment / accrual |
| NCT02300935 | Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | Phase 1 | withdrawn | Nov 25, 2014 | SCRI Development Innovations, LLC | Study concept was terminated. | Other (stated, no rule matched) |
| NCT01875653 | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma | Phase 3 | terminated | Jun 12, 2013 | Lisata Therapeutics, Inc. | not stated | Not stated |
| NCT01988831 | Efficacy of Propranolol Treatment to Prevent Melanoma Progression | Phase 2 | suspended | Nov 20, 2013 | University Hospital, Geneva | We must delay the study for some financial reasons | Funding |
| NCT03518229 | Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors | N/A | withdrawn | May 8, 2018 | University of Minnesota | Converted from a pilot into a larger study which we will enter as a new protocol | Other (stated, no rule matched) |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing…(N1) | — | terminated | Sep 14, 2016 | CureOne | Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. | Other (stated, no rule matched) |
| NCT01191034 | Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Aug 30, 2010 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completion after 2 patients then stop due to end of validity of vaccine peptide | Other (stated, no rule matched) |
| NCT01723813 | Peptide Vaccinations Plus GM-CT-01 in Melanoma | Phase 1 / Phase 2 | terminated | Nov 8, 2012 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | due to end of validity of peptide vaccine | Other (stated, no rule matched) |
| NCT00365937 | Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides | Phase 1 / Phase 2 | terminated | Aug 18, 2006 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | New regulatories of the peptides by the pharmaceutical company (the seller) | Sponsor / business decision |
| NCT01813214 | The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma | Phase 2 | terminated | Mar 18, 2013 | Georgetown University | Recruitment difficulties. | Enrollment / accrual |
| NCT02339987 | Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration | — | terminated | Jan 16, 2015 | Saint John's Cancer Institute | original PI left institute, no plan to continue using samples | Investigator |
| NCT02314143 | Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK… | Phase 2 | terminated | Dec 11, 2014 | GlaxoSmithKline | The study was terminated early due to slow enrollment and limited numbers of viable tissue samples. | Enrollment / accrual |
| NCT02068079 | A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic… | Phase 1 | withdrawn | Feb 20, 2014 | Duke University | not stated | Not stated |
| NCT01542255 | Metronomic Therapy in Patients With Metastatic Melanoma | Phase 2 | terminated | Mar 2, 2012 | Dartmouth-Hitchcock Medical Center | Low accrual not allowing to support statistical endpoints | Enrollment / accrual |
| NCT01350401 | Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous… | Phase 1 / Phase 2 | terminated | May 9, 2011 | Adaptimmune | Lack of enrollment | Enrollment / accrual |
| NCT01457131 | Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the… | Phase 1 | terminated | Oct 21, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 24, 2020source: clinicaltrials